13 Best Get Rich Fast Stocks to Buy Right Now

6. ProKidney Corp. (NASDAQ:PROK)

Upside Potential as of December 24, 2025: 152.92%

Number of Hedge Fund Holders: 9

Share Price as of December 24, 2025: $2.57

As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside potential of 152.92%. Among the analysts bullish on the stock is Joseph Pantginis, an analyst at H.C. Wainwright, who assumed coverage on the company with a ‘Buy’ rating and a $12 price target on December 16, according to TheFly. His price target implies about 367% upside from the current price.

With ProKidney Corp. (NASDAQ:PROK) initiating a fresh approach to “postponing progressive kidney dysfunction,” the analyst believes the company’s lead asset, rilparencel, exhibits the potential to redefine how chronic kidney disease is treated.

H.C. Wainwright highlighted that rilparencel, an investigational autologous cell therapy for patients living with chronic kidney disease and type 2 diabetes, has already demonstrated promising results across several Phase 1 and 2 trials. This includes meaningful advancements in estimated glomerular filtration rate (eGFR) drops, a positive safety profile, and a slowed progression to dialysis.

With that said, the company’s current Phase 3 PROACT 1 trial, which is totally in line with its Phase 2 design, has been awarded FDA approval for using eGFR slope as a surrogate endpoint. Through an accelerated regulatory approval process, this could also back a Biologics License Application (BLA) filing.

ProKidney Corp. (NASDAQ: PROK) is a North Carolina-based clinical-stage biotechnology company that provides a cell therapy platform for treating various chronic kidney diseases. Incorporated in 2015, the company is committed to “transforming the treatment landscape for chronic kidney disease.”